Novo Nordisk Raises Full-Year Outlook on GLP-1 Momentum, Q3 Profit Jumps 27%

  • Q3 2026 adjusted operating profit increased 27% at CER to DKK 31,720 million, driven by GLP-1 sales growth and favorable comparison base.
  • Reported operating profit decreased 9% at CER due to DKK 8.7 billion in non-cash impairment charges related to ziltivekimab and manufacturing network right-sizing.
  • Wegovy® pill launched in 8 markets, maintaining over 50% US market share in branded obesity.
  • Ozempic® pill launched in the US in May, with weekly new-to-brand prescriptions up around 100% compared to pre-launch levels.
  • Full-year outlook raised: adjusted sales and operating profit growth now expected to be -2% to +2% at CER.

Novo Nordisk's strong Q3 performance underscores the continued dominance of GLP-1 therapies in the obesity and diabetes markets. The company's ability to raise its full-year outlook despite impairment charges highlights the resilience of its core franchises. The strategic focus on expanding access and advancing the pipeline positions Novo Nordisk to maintain its leadership in a highly competitive landscape. The global roll-out of next-generation products like Ozempic® 2.0 mg and Wegovy® 7.2 mg single-dose pen will be key to sustaining growth.

Pipeline Execution
The pace at which CagriSema and zenagamtide advance through clinical trials will determine Novo Nordisk's long-term competitive edge in obesity and diabetes treatments.
Regulatory Dynamics
The timing and outcome of the EU approval for Frehemgo® and the US regulatory review for denecimig will impact Novo Nordisk's ability to expand its portfolio in blood and endocrine disorders.
Market Penetration
Whether Novo Nordisk can sustain the momentum of Wegovy® and Ozempic® in international markets will be critical for meeting revised full-year outlook expectations.